Theralase Technologies Inc. (TSXV:TLT)
0.2300
0.00 (0.00%)
May 22, 2026, 3:17 PM EST
Theralase Technologies Revenue
In the year 2025, Theralase Technologies had annual revenue of 816.47K CAD, down -20.99%. Theralase Technologies had revenue of 225.90K in the quarter ending December 31, 2025, a decrease of -44.96%.
Revenue
816.47K
Revenue Growth
-20.99%
P/S Ratio
77.70
Revenue / Employee
40.82K
Employees
20
Market Cap
63.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 816.47K | -216.96K | -20.99% |
| Dec 31, 2024 | 1.03M | -36.88K | -3.45% |
| Dec 31, 2023 | 1.07M | -68.26K | -6.00% |
| Dec 31, 2022 | 1.14M | 357.93K | 45.85% |
| Dec 31, 2021 | 780.64K | -148.48K | -15.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Profound Medical | 26.26M |
| Aurora Spine | 25.18M |
| Perimeter Medical Imaging AI | 3.16M |
| Cheelcare | 1.63M |
| Frequency Exchange | 886.47K |
| Conavi Medical | 706.00K |
| MedX Health | 473.27K |
| Ventripoint Diagnostics | 179.93K |
Theralase Technologies News
- 2 days ago - Theralase(R) Closes C$4.8 Million Offering - Newsfile Corp
- 10 days ago - Theralase Technologies Earnings Call Transcript: Q4 2025 - Transcripts
- 10 days ago - Theralase Technologies Registration statement: Q4 2025 - Filings
- 10 days ago - Theralase Technologies Registration statement: Q4 2025 - Filings
- 10 days ago - Theralase Technologies Earnings release: Q4 2025 - Filings
- 16 days ago - Theralase(R) Announces $4 Million Brokered LIFE Offering - Newsfile Corp
- 17 days ago - Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update - Newsfile Corp
- 5 weeks ago - Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study - Newsfile Corp